# Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients

> **Open Intelligence Dossier** · First detected: 2026-09-21 19:20 UTC · Category: Business

## Executive Summary
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Hilton Head Island Packet, newsquawk.com, WTVB and Seeking Alpha. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Yahoo Finance | Lilly Gains as Novo Wins a Lower-Dose Weight-Loss Round | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxPYlFUTFFSQW1NMVVGVHZtdmhMcS03aXBSOXV4eTRtWVBzemVkNW5vdE80VnIxR09iNGFmS1llVmFvWUYxcWZhV0daNzJ3T1RPa1BrVGdNZ1FyelZ5YzZlbnBIZS04MmExcC0zWEt4blFrSnFqcjh3VnFnN29SdEtSNmlFU21ibWRFQXNaZHRBQUJadw?oc=5) |
| Hilton Head Island Packet | Novo says its next-gen obesity drug tops Lilly rival in late-stage study | [Source Link](https://news.google.com/rss/articles/CBMiaEFVX3lxTFA5VjZja19PTzYzeUZ5cGdFUGlzY2pXa3JidjFjQUJCVlE0NDVqMWNZdkt4V1B5WldGX2d3bHZ2SUxBYVh3VkdVYkJITGRlQzJUWkc4YUp6Z1JYWjdYcDVDQ25WYUpWQXV6?oc=5) |
| newsquawk.com | Novo Nordisk (NOVOB DC) announces topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema, with CagriSema proving superior to tirzepatide and weight loss of 21% | [Source Link](https://news.google.com/rss/articles/CBMirwJBVV95cUxPSXNNaWU1eUpFbldEcG5CQm1fTWlGejZEc3VHWWJteFlQYjVsMThvbnlmRXA3RDdnX3pyaGxlc0NidHVRRVpZMGxfUUVxSnMySjBYd05oZzctNkVsN2Q4VkQ2MkRCZFNsa0NYZ09pRGZiR1I5aUhnUlVPLVREUUNVVmxfdXdvRW5IQzBzbGE1bWEtWm8xazlaeDFuc3N4MzNGVDRTS0xXUHE3OGR1NjUtMlpEaThvY1J4LWNhMlMxUTVBckNybG9sdTVqUkRxaGUxMlJEOHNRM1JPTTlYR0JfZGFsTUs4Um1VaGMtbUpDTWVKRTMxV2w4M1JmT3JtOE96R0ZHQ2FtZkdGU3dmNGpnYmlZNGRtSDdTYWk0d0I3LTZ1al9fNG9HdS04MkJXYzA?oc=5) |
| WTVB | Novo says CagriSema tops Lilly rival in diabetes patients for weight loss | [Source Link](https://news.google.com/rss/articles/CBMipgFBVV95cUxNbDdjOVYxcHo4YnlOci0wYXlDVlcxeld3XzVzRGFMMk11SXZuVUNzNENPalo4YThKZlVIQWVfcHdFRWI4MHRxVjJmblJFOXllYXd4OTVsMHJRMjFrOFR1ancwenkzaEQ0OXgyNkpocFZ2RTM3V0UybFFSTGI1NFRNX3VVM2tWRnJuekt1dFZ3T1pSZWRYOWd0TDU2cjRkc0o3dnZCc2RR?oc=5) |
| Seeking Alpha | Novo Nordisk says CagriSema bests Eli Lilly's Zepbound (NVO:NYSE) | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxNQURBZVc1QUxMN0t4eFp3RWpCUjBGVlc2dWpjRlN2ZzBJbUtxOFFZRkZFRXhFaUM3bUtnRjltWm9mclJPdVJlOFV6d2w4ZFRzM1M3dXhRVVNUQVRzUnlfaFNUY1pTbHFqb1QyeVFmcHJiMHh1UlhKb0tSVG5uMWh1SWdXbmI3X3BtQ2NmRWFTeFAzUEdu?oc=5) |
| PharmaLive | Novo’s CagriSema delivers superior weight loss versus tirzepatide | [Source Link](https://news.google.com/rss/articles/CBMilwFBVV95cUxNMjNQYURLMllzRVBBRWlYU0JxV1hqWUpMTV91RDJJX19zRk9UbDZUVktUSHBBUlFUQk5xOG9jM2dhQXB6LU1pbGZNT0EyUHY0aWlIbl9rcXVBak9CakdEaHZZV29GWURpY2NlYkNUekpySUY1LVlCQ2lEU1oxa2Y0NkpvRWZUR25mOXlYeUNiMW1DYVJPWXVN?oc=5) |
| Reuters | Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients | [Source Link](https://news.google.com/rss/articles/CBMi2AFBVV95cUxPSHlFWGtzanhmbXJ1bnRkWUREdHp5TVZGT3FxMVBTVFRranIyZUhCWWlHa2dmcUxsLTczakxobmtfaHlaZ2UyZFBidEFubjJ5ZkZzdFVwWkxUMEVUdTBQWFdQYmw3bjVaT0RzQXpHTkRNeHhrcTRRV1Flb2V0T2k4bW5rb2RvdW9FdGhPRUdCZElmVU4zQzJLLWRrV1daUjhXQlNzcGx3eGN3dWNCX09pY3JvUC10T2NzMEZqZHkyc042TWtQQTJQcThmemNxQUFRbG1wV3NqcUs?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-21/novo-says-cagrisema-shows-greater-weight-loss-than-lilly-rival-in-diabetes*